Mirapex

DRUG2 trials

Sponsors

Boehringer Ingelheim, Rajesh Pahwa, MD

Conditions

Parkinson Disease

Phase 3

Pramipexole Conversion to Ropinirole Controlled Release (CR)

CompletedNCT00275275

Rajesh Pahwa, MDParkinson Disease

Start: 2006-01-31End: 2008-05-31Updated: 2012-08-24

Phase 4

Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients

CompletedNCT00144300

Boehringer IngelheimParkinson Disease

Start: 2005-01-31Updated: 2014-03-14

Related Papers

Ophthalmologic Baseline Characteristics and 2-Year Ophthalmologic Safety Profile of Pramipexole IR Compared with Ropinirole IR in Patients with Early Parkinson’s Disease

Parkinson s Disease2016-01-015 citations